These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8382722)

  • 1. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
    Bernstein DI; Miller RL; Harrison CJ
    J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs.
    Bernstein DI; Harrison CJ; Tepe ER; Shahwan A; Miller RL
    Vaccine; 1995 Jan; 13(1):72-6. PubMed ID: 7762282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
    Harrison CJ; Miller RL; Bernstein DI
    Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
    J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development.
    Bernstein DI; Miller RL; Harrison CJ
    Antiviral Res; 1993 Jan; 20(1):45-55. PubMed ID: 8457147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
    Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
    Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod.
    Miller RL; Imbertson LM; Reiter MJ; Gerster JF
    Antiviral Res; 1999 Nov; 44(1):31-42. PubMed ID: 10588331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
    Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
    J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines.
    Bernstein DI; Stanberry LR; Kappes JC; Burke RL; Myers MG
    J Infect Dis; 1988 Jun; 157(6):1178-86. PubMed ID: 2836519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs.
    Harrison CJ; Miller RL; Bernstein DI
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2059-64. PubMed ID: 7811019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.